Detalhe da pesquisa
1.
The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study.
Br J Haematol
; 204(4): 1271-1278, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-37957542
2.
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study.
Haematologica
; 107(7): 1633-1642, 2022 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34407602
3.
Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.
BMC Cancer
; 22(1): 231, 2022 Mar 03.
Artigo
Inglês
| MEDLINE | ID: mdl-35236331
4.
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma.
Ann Hematol
; 99(12): 2837-2846, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-32314038
5.
Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.
Am J Hematol
; 95(12): 1503-1510, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32815559
6.
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
Haematologica
; 102(4): 765-772, 2017 04.
Artigo
Inglês
| MEDLINE | ID: mdl-28011903
7.
No evidence of relation between working memory and perception of interrupted speech in young adults.
J Acoust Soc Am
; 138(2): EL145-50, 2015 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-26328740
8.
Automated Lugano Metabolic Response Assessment in 18F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on 18F-Fluorodeoxyglucose-Positron Emission Tomography.
J Clin Oncol
; : JCO2301978, 2024 Jun 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38843483
9.
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.
J Clin Oncol
; 42(5): 550-561, 2024 Feb 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38096461
10.
Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study.
Clin Lymphoma Myeloma Leuk
; 23(1): 40-48, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36379880
11.
A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials.
EJHaem
; 4(4): 1042-1051, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-38024624
12.
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study.
Hemasphere
; 7(7): e919, 2023 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-37404773
13.
Patient-reported outcomes provide prognostic information for survival in patients with diffuse large B-cell lymphoma: Analysis of 1239 patients from the GOYA study.
Cancer Med
; 11(17): 3312-3322, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35322932
14.
Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial.
Hemasphere
; 6(3): e699, 2022 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-35233508
15.
Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study.
J Nucl Med
; 63(8): 1149-1154, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34857656
16.
Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study.
Chin Med J (Engl)
; 135(4): 433-440, 2021 Sep 16.
Artigo
Inglês
| MEDLINE | ID: mdl-35194005
17.
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.
Blood Cancer J
; 11(8): 147, 2021 08 20.
Artigo
Inglês
| MEDLINE | ID: mdl-34417444
18.
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA.
Blood Adv
; 5(5): 1283-1290, 2021 03 09.
Artigo
Inglês
| MEDLINE | ID: mdl-33651099
19.
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.
Blood Adv
; 5(15): 2935-2944, 2021 08 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34323957
20.
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment.
Blood Adv
; 5(15): 2945-2957, 2021 08 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34323958